CN101912437B - Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof - Google Patents
Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof Download PDFInfo
- Publication number
- CN101912437B CN101912437B CN201010244800XA CN201010244800A CN101912437B CN 101912437 B CN101912437 B CN 101912437B CN 201010244800X A CN201010244800X A CN 201010244800XA CN 201010244800 A CN201010244800 A CN 201010244800A CN 101912437 B CN101912437 B CN 101912437B
- Authority
- CN
- China
- Prior art keywords
- parts
- colla
- chemotherapy
- radiotherapy
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy. The Chinese medicinal composition is prepared from the following raw materials in part by weight: 9 to 15 parts of tortoise-plastron glue, 9 to 15 parts of deerhorn glue, 9 to 15 parts of donkey-hide gelatin, 9 to 15 parts of dried human placenta, 9 to 15 parts of drynaria rhizome, 7 to 13 parts of pseudo-ginseng root, 9 to 15 parts of suncured ginseng and 1 to 6 parts of fried licorice root. The Chinese medicinal composition has the effects of tonifying qi, enriching blood, tonifying kidney and replenishing essence, is used for improving the bone marrow depression caused by the radiotherapy and chemotherapy and symptoms such as weakness, palpitation, shortness of breath, pale face, pale tongue, white fur, weak pulse and the like caused by hypocytosis, can effectively improve the bone marrow depression reaction caused by the radiotherapy and chemotherapy and improve the compliance of tumor patients with radiotherapy and chemotherapy. The invention also discloses a preparation method of the Chinese medicinal composition.
Description
Technical field
The present invention relates to Chinese medicine composition, especially a kind of myelosuppressive compound Chinese medicinal preparation of caused by radiotherapy and chemotherapy of improving.
Background technology
Under the normal condition, granulocytic aging death, destruction and discharge are relative steady state in the propagation of bone marrow inner cell, maturation and release and the peripheral blood.Some tumor has been destroyed this balance in its therapeutic process, leukopenia even pancytopenia promptly occur.Various lonizing radiation the inhibition of bone marrow is more common in the tumour radiotherapy and radiotherapy after.Lonizing radiation not only can make bone marrow depression, and can the direct killing granulocyte or cause chromosomal change, its microcirculatory change often the reasonable time in can not get recovering.The chemotherapeutics of radiotherapy sensitization effect such as DNR, ADM etc. have also increased side effect when increasing radiation sensitivity.Because bone marrow and lymphoid tissue molecular marker for increased proliferation, differentiation degree is low, extremely sensitive to lonizing radiation, so the bone marrow damage degree depends on size, range of exposures and position, the irradiation time etc. of radiological dose. the bone marrow depression of caused by radiation is light far beyond chemotherapy, mainly influence granulocyte series, large tracts of land can influence BPC.Most cancer therapy drugs all have bone marrow inhibition in various degree.Chemotherapeutics (antitumor drug) can act on the different links in cancer cell multiplication cycle, suppresses DNA division growth ability, thereby plays the tumor treatment effect.But because chemotherapeutics lacks selectivity, also can kill many normal marrow cells when killing the massive tumor cell, especially granulocyte series be had the greatest impact, thereby bone marrow depression occurs, clinical manifestation is a leukopenia, or pancytopenia.In the chemotherapy process, along with the chemotherapeutics increase of cumulant in vivo, its bone marrow depression also increases the weight of gradually.The bone marrow depression of most cancer therapy drugs comes across 1～3 week after the medication, continues to recover in 2～4 weeks.But HN2 suppresses lymphocyte, but occurs in after the administration 24 hours.It is slower that the bone marrow depression of nitrosourea occurs, and minimum saw for the 3rd～4 week, and convalescent period also was about for 6～8 weeks.Most medicines are accompanied the corresponding decline of platelet BPC to suppress WBC, minority medicine such as MMC, and CBP is to suppress BPC.
Bone marrow depression is that tumor is put, the modal side effect of chemotherapy, and based on leukopenia, erythrocyte, platelet all can have decline in various degree, and severe patient can cause infection, anemia and hemorrhage, causes treatment to be interrupted.Leukogenic effects such as conventional Western medicine such as batilol, leucogen, adenine phosphate are slow, and therapeutic effect is not obvious, and granulocyte colony-stimulating factor is difficult to conventional the application because of costing an arm and a leg.
The traditional Chinese medical science is thought, radiotherapy ray and chemotherapeutics belong to " heresy of pyretic toxicity ", in invade behind the human body easily yin-damaging and Qi consuming, decrease the smart liquid that burns, cause visceral dysfunction, have a strong impact on source of generating QI and blood, the disease that QIYINLIANGXU occurs, so put, leukopenia caused by cancer chemotherapy disease belongs to the deficiency syndrome category, its main pathogenesis and spleen kidney are in close relations, thus benefiting QI and nourishing blood, warming and recuperating the spleen and kidney, benefit bone life marrow, enriching kidney essence be alleviate put, the myelosuppressive basic rule of treatment due to the chemotherapy.By traditional Chinese medical herbal treatment, can effectively improve the leukopenia or the pancytopenia of caused by radiotherapy and chemotherapy, make tumor patient pass through therapeutic scheme smoothly.But be not that the Chinese medicine that has effects such as benefiting QI and nourishing blood, warming and recuperating the spleen and kidney, the living marrow of benefit bone, enriching kidney essence arbitrarily all can have the myelosuppressive effect of the caused by radiotherapy and chemotherapy of improvement with the arbitrary proportion combination.
Summary of the invention
The purpose of this invention is to provide a kind of myelosuppressive Chinese medicine composition of caused by radiotherapy and chemotherapy that improves, has vigorate qi and replenish the blood, the effect of bone and muscle strengthening, be used for the caused by radiotherapy and chemotherapy bone marrow depression, that cytopenia occurs is weak, cardiopalmus, breathe hard, pale complexion, the pale tongue tongue is white, weak pulse is unable to wait disease, can effectively improve caused by radiotherapy and chemotherapy bone marrow depression reaction, improve the compliance of tumor patient chemicotherapy.
Another object of the present invention provides a kind of preparation method of above-mentioned Chinese medicine composition.
A kind of myelosuppressive Chinese medicine composition of caused by radiotherapy and chemotherapy that improves, it is made by following weight parts proportion raw material medicine:
Colla Plastri Testudinis 9-15 part, Colla cornus cervi 9-15 part, Colla Corii Asini 9-15 part, Placenta Hominis 9-15 part, Rhizoma Drynariae 9-15 part,
Radix Notoginseng 7-13 part, Radix Ginseng 9-15 part, Radix Glycyrrhizae Preparata 1-6 part.
The weight portion proportioning of above-mentioned each crude drug can be preferably:
Colla Plastri Testudinis 10-14 part, Colla cornus cervi 10-14 part, Colla Corii Asini 10-14 part, Placenta Hominis 10-14 part, Rhizoma Drynariae 10-14 part,
Radix Notoginseng 8-12 part, Radix Ginseng 10-14 part, Radix Glycyrrhizae Preparata 1-5 part.
The weight portion proportioning of above-mentioned each crude drug can be more preferably:
Colla Plastri Testudinis 11-13 part, Colla cornus cervi 11-13 part, Colla Corii Asini 11-13 part, Placenta Hominis 11-13 part, Rhizoma Drynariae 11-13 part,
Radix Notoginseng 9-11 part, Radix Ginseng 11-13 part, Radix Glycyrrhizae Preparata 2-4 part.
The weight portion proportioning of above-mentioned each crude drug can be more preferably:
12 parts of Colla Plastri Testudiniss, 12 parts of Colla cornus cervis, 12 parts in Colla Corii Asini, 12 parts of Placenta Hominiss, 12 parts of Rhizoma Drynariae, 10 parts of Radix Notoginseng,
12 parts of Radix Ginseng, 3 parts of Radix Glycyrrhizae Preparatas.
The dosage form of pharmaceutical composition of the present invention can be selected from any one pharmaceutically feasible oral Pharmaceutical dosage forms such as granule, drop pill, tablet, hard capsule, soft capsule, oral liquid.
Above-mentioned Chinese medicine composition can prepare by the method that comprises following key step:
(1) Placenta Hominis, Radix Notoginseng powder are broken into fine powder, standby;
(2) Rhizoma Drynariae, Radix Ginseng and Radix Glycyrrhizae Preparata are merged, decoct with water extraction, filter, filtrate concentrates, and adds Colla Plastri Testudinis, Colla cornus cervi, Colla Corii Asini, Placenta Hominis fine powder, Radix Notoginseng fine powder, mixing, and drying obtains mixed extract;
(3) get the mixed extract that step (2) obtains, make the medicine (according to the conventional preparation method of various peroral dosage form medicines, adding proper quantity of medicinal auxiliary material that can be suitable) of peroral dosage form.
Compared with prior art, the invention has the beneficial effects as follows:
Medicine of the present invention has vigorate qi and replenish the blood, the effect of bone and muscle strengthening, be used for the caused by radiotherapy and chemotherapy bone marrow depression, that cytopenia occurs is weak, cardiopalmus, breathe hard, pale complexion, the pale tongue tongue is white, and the unable grade of weak pulse disease can effectively be improved caused by radiotherapy and chemotherapy bone marrow depression reaction, do the toleration of high patient, improve the compliance of tumor patient chemicotherapy chemicotherapy.
And the crude drug of Chinese medicine composition of the present invention is conventional Chinese medicine, and toxic and side effects is little, and safety is good; And raw material is easy to get, and is with low cost.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following embodiment.
Embodiment 1-8
According to proportioning raw materials and the dosage form of listed each embodiment in the following table 1, preparation improves the myelosuppressive Chinese medicine composition 1-8 of caused by radiotherapy and chemotherapy respectively.
The parts by weight of raw materials proportioning of each embodiment of table 1 and dosage form (unit: g)
Aforementioned pharmaceutical compositions 1-8 all adopts the method preparation that comprises following key step:
(1) Placenta Hominis, Radix Notoginseng powder are broken into fine powder, standby;
(2) Rhizoma Drynariae, Radix Ginseng and Radix Glycyrrhizae Preparata are merged, decoct with water extraction, filter, filtrate concentrates, and adds Colla Plastri Testudinis, Colla cornus cervi, Colla Corii Asini, Placenta Hominis fine powder, Radix Notoginseng fine powder, mixing, and drying obtains mixed extract;
(3) get the mixed extract that step (2) obtains, add adjuvant, make the medicine of described peroral dosage form respectively.
For confirming the curative effect and the advantage thereof of pharmaceutical composition of the present invention, the inventor is an investigational agent with the pharmaceutical composition of the foregoing description 1-8, and having carried out following pharmacodynamics test is proved:
The pharmacodynamics test of dialogue impact cell
1, principle: cyclophosphamide belongs to the Cell cycle non-specific chemotherapeutics, due to the characteristics of animal model be bone marrow depression, it mainly shows is that leukopenia is obvious, and leukocytic variation can reflect more sensitively that all hemopoietic function of bone marrow suppresses degree.
2, material:
Animal: Kunming mouse, body weight 18-22g, male and female half and half, Mus 8 weeks of age.Equipment: Cel12DYN blood cell automatic counter for counting.
3, medicine and reagent:
Trial drug 1-8 (being respectively the Chinese medicine composition of the foregoing description 1-8);
Cyclophosphamide (CTX): 5mg/ sheet, Hengrui Medicine Co., Ltd., Jiangsu Prov..
4, test method:
(1) making of model
Adopt the method inject cyclophosphamide every day, except that the normal control group, test beginning in the 1st day certainly, every mice is pressed the continuous intraperitoneal injection of cyclophosphamide of 100 μ L/20g (100mg/kg) body weight dosage every day.Every day 1 time, inject altogether 7 times.
(2) test method and result
120 mices are divided into 10 groups at random, 12 every group.Be normal control group, model group, trial drug group.The normal control group, the normal raising do not give special handling; Normal group and model group dosage gavage normal saline, and the trial drug group gavages medicinal liquid.The amount of gavaging is: the 20mL/kg body weight.Every day 1 time, totally 10 days.
Detect index: the peripheral blood leucocyte counting.
Result of the test is shown in following table 2.
The influence of table 2 pair mice peripheral blood leucocyte counting
Annotate: compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with the cyclophosphamide group; Compare Δ P＜0.05, Δ Δ P＜0.01, Δ Δ Δ P＜0.001 with normal group.
Table 2 result shows that the different embodiment groups of this product 12g raw medicinal herbs/kg dosage all have the effect (P＜0.01) that significantly promotes in various degree to the peripheral blood leucocyte counting, illustrates that this product can improve the caused by radiotherapy and chemotherapy bone marrow depression.
Claims (6)
1. one kind is improved the myelosuppressive Chinese medicine composition of caused by radiotherapy and chemotherapy, and it is made by following weight parts proportion raw material medicine: Colla Plastri Testudinis 9-15 part, Colla cornus cervi 9-15 part, Colla Corii Asini 9-15 part, Placenta Hominis 9-15 part, Rhizoma Drynariae 9-15 part, Radix Notoginseng 7-13 part, Radix Ginseng 9-15 part, Radix Glycyrrhizae Preparata 1-6 part.
2. Chinese medicine composition according to claim 1, it is characterized in that: the weight portion proportioning of described each crude drug is: Colla Plastri Testudinis 10-14 part, Colla cornus cervi 10-14 part, Colla Corii Asini 10-14 part, Placenta Hominis 10-14 part, Rhizoma Drynariae 10-14 part, Radix Notoginseng 8-12 part, Radix Ginseng 10-14 part, Radix Glycyrrhizae Preparata 1-5 part.
3. Chinese medicine composition according to claim 1, it is characterized in that: the weight portion proportioning of described each crude drug is: Colla Plastri Testudinis 11-13 part, Colla cornus cervi 11-13 part, Colla Corii Asini 11-13 part, Placenta Hominis 11-13 part, Rhizoma Drynariae 11-13 part, Radix Notoginseng 9-11 part, Radix Ginseng 11-13 part, Radix Glycyrrhizae Preparata 2-4 part.
4. Chinese medicine composition according to claim 1 is characterized in that: the weight portion proportioning of described each crude drug is: 12 parts of Colla Plastri Testudiniss, 12 parts of Colla cornus cervis, 12 parts in Colla Corii Asini, 12 parts of Placenta Hominiss, 12 parts of Rhizoma Drynariae, 10 parts of Radix Notoginseng, 12 parts of Radix Ginseng, 3 parts of Radix Glycyrrhizae Preparatas.
5. according to each described Chinese medicine composition among the claim 1-4, it is characterized in that: the dosage form of described medicine is selected from granule, drop pill, tablet, hard capsule, soft capsule, oral liquid.
6. the preparation method of the described Chinese medicine composition of claim 1 comprises following key step:
(1) Placenta Hominis, Radix Notoginseng powder are broken into fine powder, standby;
(2) Rhizoma Drynariae, Radix Ginseng and Radix Glycyrrhizae Preparata are merged, decoct with water extraction, filter, filtrate concentrates, and adds Colla Plastri Testudinis, Colla cornus cervi, Colla Corii Asini, Placenta Hominis fine powder, Radix Notoginseng fine powder, mixing, and drying obtains mixed extract;
(3) get the mixed extract that step (2) obtains, make the medicine of peroral dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010244800XA CN101912437B (en) | 2010-08-04 | 2010-08-04 | Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010244800XA CN101912437B (en) | 2010-08-04 | 2010-08-04 | Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101912437A CN101912437A (en) | 2010-12-15 |
| CN101912437B true CN101912437B (en) | 2011-12-07 |
Family
ID=43320184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010244800XA Expired - Fee Related CN101912437B (en) | 2010-08-04 | 2010-08-04 | Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101912437B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666782A (en) * | 2015-02-26 | 2015-06-03 | 王晓辉 | External application traditional Chinese medicine preparation for preventing bone marrow suppression after chemotherapy |
| CN106552107A (en) * | 2016-11-07 | 2017-04-05 | 林胜友 | It is a kind of to adjust immunosuppressant Chinese medicine composition after chemotherapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086296C (en) * | 1999-03-25 | 2002-06-19 | 王淳 | Compound donkey-hide gelatin preparation for preventing arrest of bone marrow in chemotherapy and radiotherapy and preparing process thereof |
-
2010
- 2010-08-04 CN CN201010244800XA patent/CN101912437B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101912437A (en) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN102133384A (en) | Ginger and dried orange peel composition, preparation method thereof and application of ginger and dried orange peel composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy | |
| JP2016534074A (en) | Use of icaritin in the manufacture of a medicament for preventing or treating cytopenias | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| JP2019535833A (en) | Traditional Chinese medicine composition for tumor treatment and its production method and use | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101912437B (en) | Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof | |
| CN102370645B (en) | Anticancer drug composition | |
| CN104434939A (en) | Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN100455322C (en) | A Chinese medicine for treating cancer | |
| CN106163515A (en) | Anticancer and agents for relieving side effects | |
| CN102526024B (en) | Anticancer pharmaceutical composition | |
| CN102091312A (en) | Ginger and wild pepper composition and preparation method thereof, and application of ginger and wild pepper composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN101439088B (en) | Medicament for promoting leucocyte hyperplasia | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN106138697B (en) | Chinese medicinal composition for preventing complications and relieving side effects of radiotherapy and chemotherapy of tumor patients | |
| CN103191267A (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN102309493B (en) | Anti-cancer medicinal composition | |
| CN101721471B (en) | Leucocyte-raising medicine containing leucogen | |
| CN102058668A (en) | Traditional Chinese medicinal preparation for treating primary thrombocytopenia | |
| CN114246906A (en) | Application of traditional Chinese medicine composition in preparation of medicines for preventing and treating bone marrow suppression | |
| CN101773660B (en) | Medicament containing anubi-polypeotide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengdu Huaxi Haiqi Medical Technology Co., Ltd. Assignor: West China Hospital of Sichuan University Contract record no.: 2012510000008 Denomination of invention: Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof Granted publication date: 20111207 License type: Exclusive License Open date: 20101215 Record date: 20120312 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20140804 |
|
| EXPY | Termination of patent right or utility model |